Heart Disease & Cardiology Clinical Trials Update: Week 25, 2026

Published June 19, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI

This Phase 4 trial is exploring a new combination of blood-thinning medications, dabigatran and ticagrelor, for people with atrial fibrillation and acute coronary syndrome who are undergoing a procedure to open blocked heart arteries. The goal is to reduce the risk of bleeding while still preventing dangerous blood clots. If the treatment proves safe and effective, it could offer patients a better balance between preventing stroke and avoiding bleeding complications.

Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity

This Phase 4 study is testing a new drug called mazdutide in patients who have coronary heart disease and are overweight or obese. The research focuses on whether this medication can slow down the buildup of plaque inside the arteries, which is a key cause of heart attacks. Successful results could lead to a new treatment option that helps lower heart risks in this high-risk group.

LA-HCM Study: Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain

This Phase 3 trial is looking at the blood thinner rivaroxaban to prevent stroke in patients with hypertrophic cardiomyopathy who have early signs of abnormal heart function but no symptoms yet. By preventing blood clots before problems develop, this treatment might reduce the risk of stroke and improve long-term heart health for those affected by this heart muscle condition.

The Clinical Outcomes and Therapeutic Effects in Patients With Cardiac Implantable Electronic Device-detected Subclinical and Clinical Atrial Fibrillation

This Phase 4 trial is studying whether starting early treatment to control heart rhythm, combined with managing other risk factors, can stop the worsening of atrial fibrillation detected by implanted heart devices. Early intervention may help prevent serious complications like stroke and heart failure, offering a new approach to managing this common heart rhythm disorder.

A Coronary Computed Tomography Angiography-guided Intervention for High Risk Cardiovascular Disease Population in Rural China

This study is testing whether using detailed heart artery imaging to guide treatment decisions can better reduce heart problems in people at high risk of coronary artery disease. If effective, this approach could lead to more personalized care that helps prevent heart attacks and other serious events, especially in rural areas where access to advanced care is limited.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.